ClinicalTrialsFinder
RecruitingPhase 1NCT07187973

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease

Sponsor

Disc Medicine, Inc

Enrollment

24 participants

Start Date

Jan 6, 2026

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease

Summary

This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DISC-3405 for people with sickle cell disease. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDISC-3405

DISC-3405 is administered subcutaneously.

Locations(6)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Emory University

Atlanta, Georgia, United States

Augusta University

Augusta, Georgia, United States

Innovative Hematology - Indiana Hemophilia & Thrombosis Center

Indianapolis, Indiana, United States

Mount Sinai Hospital

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07187973

Related Trials

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT059040931 location

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

NCT075991761 location

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

NCT069440671 location

Functional Ovarian Reserve in Sickle Cell Disease

NCT073922161 location